Amgen Inc. closed $13.93 short of its 52-week high ($346.85), which the company reached on July 25th.

False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Shares of Amgen Inc. AMGN slumped 0.73% to $332.80 Tuesday, on what proved to be an all-around mixed trading session for the ...

In a report released today, Michael Yee from Jefferies assigned a Buy rating to Amgen (AMGN – Research Report), with a price target of ...

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

With a sold-out crowd and a ton of momentum, Rory McIlroy appeared poised to post his first DP World Tour victory on Northern ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...

The FTC said in its complaint that Amgen would be able to leverage its position with insurance companies and pharmacy benefit managers wanting access to its blockbuster drugs. President Biden is ...

Rory McIlroy is on familiar soil. Eleven days after a tie for ninth in the Tour Championship, McIlroy fired a first-round 68 ...

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types THOUSAND OAKS, Calif., Sept. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the presentation ...

Rory McIlroy has 17 DP World Tour wins. He's 18 holes from adding an 18th. McIlroy tied for low the round of the day on ...